MDGL — MADRIGAL PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1157601 ·
Last close
$517.04
Market Cap
$11.95B
52W High
$615.00
52W Low
$393.61
ADV30
229,662
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 364,252,000 | 324,245,000 | -56,308,000 | -57,939,000 | 1,244,645,000 | 292,726,000 | 720,921,000 |
| Mar 2026 | 311,337,000 | 284,490,000 | -92,723,000 | -94,391,000 | 1,227,327,000 | 227,033,000 | 683,873,000 |
| Dec 2025 | 321,083,000 | 296,635,000 | -59,609,000 | -58,575,000 | 1,259,589,000 | 198,693,000 | 656,900,000 |
| Sep 2025 | 287,268,000 | 269,146,000 | -113,975,000 | -114,190,000 | 1,362,457,000 | 295,694,000 | 736,725,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-197,716,000
Investing CF
$46,970,000
Financing CF
$251,044,000
CapEx
$-8,297,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.89
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,242,796,000
Inventory
$99,391,000
Receivables
$192,311,000
ST Investments
$546,027,000
EBIT TTM
$-293,588,000
Pretax Income TTM
$-325,095,000
Interest Exp TTM
$31,507,000
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,283,939,968
EBITDA
$-321,097,984
Free Cash Flow
$-80,466,248
Enterprise Value
$11,857,922,048
Total Cash
$838,753,024
Total Debt
$347,751,008
Shares Out
23,104,126
Trailing EPS
$-14.00
Book Value
$22.68
ROE
-53.3%
ROA
-17.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 958,403,000 | -300,097,000 | -288,284,000 | 1,259,589,000 | 656,900,000 | 602,689,000 | -189,553,000 |
| Dec 2024 | 180,133,000 | -497,875,000 | -465,892,000 | 1,042,247,000 | 287,864,000 | 754,383,000 | -455,572,000 |
| Dec 2023 | 0 | -380,496,000 | -373,630,000 | 640,547,000 | 235,214,000 | 405,333,000 | -324,230,000 |
| Dec 2022 | 0 | -293,571,000 | -295,350,000 | 362,572,000 | 165,183,000 | 197,389,000 | -224,857,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$9.62
Max Pain — expiry 2026-12-18
max pain strike: $620.00 · spot: $517.04 · call oi: 636 · put oi: 639
Expected Move to 2026-12-18:
±$208.29
(40.29%) —
implied range
$308.75 –
$725.33
· ATM straddle on $520.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AAVXF | Abivax S.A. | $12.13B | $139.00 | — |
| SMMT | Summit Therapeutics Inc. | $12.35B | $15.48 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.51B | $59.46 | — |
| CORT | CORCEPT THERAPEUTICS INC | $12.50B | $115.63 | — |
| ELAN | Elanco Animal Health Inc | $11.21B | $22.45 | — |
News headlines (Yahoo Finance, 1h cache)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-09-16 20:05 · Yahoo
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
2026-09-10 16:20 · Yahoo
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
2026-09-02 12:00 · Yahoo
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
2026-08-25 16:20 · Yahoo
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
2026-08-15 09:01 · Yahoo
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
2026-08-12 12:00 · Yahoo
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
2026-08-06 12:00 · Yahoo
Madrigal Pharmaceuticals (MDGL) Beat Earnings Estimates, Is It Still Below Fair Value?
2026-07-31 18:09 · Yahoo
Madrigal Pharmaceuticals Q2 Earnings Call Highlights
2026-07-30 18:04 · Yahoo
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates
2026-07-30 12:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.